Nonsquamous Nonsmall Cell Neoplasm of Lung Clinical Trial
Official title:
A Phase I/II, Open Label Study to Evaluate the Safety and Efficacy of BLEX 404Oral Liquid Combined With Pemetrexed + Cisplatin Therapy in Patients With Advanced Inoperable or Metastatic EGFR Wild-type Non-Small Cell Lung Cancer Patients
Maitake is reported with immunomodulatory functions against tumor growth in terms of its unique molecular structure, β-glucan polysaccharides within 1, 6 main chain having 1, 3 branches and a 1, 3 main chain having 1, 6 branches configuration. The β-glucan is identified as a main component of BLEX 404. Not only with therapeutic potential on several types of cancer, BLEX 404 has also shown the potential to improve hematopoiesis, granulocyte colony stimulating factor (G-CSF) production, and the cytotoxicity activity of immune cells in recent animal studies. Its antitumor effect on tumor-bearing mice is exerted by enhancing the immune system through activation of macrophages, T cells, and natural killer (NK) cells. The activation of antigen presenting cells (APCs) such as macrophages, dendritic cells (DCs) via BLEX 404 administration is in response to secretion of interleukin-12 (IL-12). BLEX 404 has been found to enhance the activity of immunocompetent cells such as helper T cells, cytotoxic T cells, and NK cells either by i.p injection or oral intake, therefore, it stimulates innate and adaptive immunity. BLEX 404 enhances hematopoiesis by increasing mouse bone marrow cell and human cord blood cell differentiation into granulocytes-macrophages (GMs), granulopoiesis and mobilization of granulocytes, and granulocyte macrophage colony-stimulating factor (GM-CSF) or G-CSF production. One related phase I healthy human trial by treating with Maitake D-fraction was examined in Italy. The published data of trial for solid tumor patients was in the year 2003 in Japan, and another for breast cancer patients was in the year 2009 in the United States executed by Memorial Sloan Kettering Cancer Center (MSKCC). Lately, same team amended IND for myelodysplastic syndromes (MDS) human trial. All those human experiences are the fundamental of developing BLEX 404 Oral Liquid.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03380871 -
A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer
|
Phase 1 | |
| Terminated |
NCT01373463 -
Cisplatin and Pemetrexed With Radiation Followed by Lobectomy
|
Phase 1 | |
| Completed |
NCT02679443 -
Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy
|
N/A | |
| Completed |
NCT02049060 -
Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin
|
Phase 1/Phase 2 | |
| Completed |
NCT02259582 -
A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT01814163 -
Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab
|
N/A | |
| Terminated |
NCT02831933 -
Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma
|
Phase 2 | |
| Terminated |
NCT02019979 -
Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC)
|
Phase 2 | |
| Completed |
NCT01705184 -
Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.
|
Phase 2 | |
| Not yet recruiting |
NCT02852798 -
Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC
|
N/A | |
| Active, not recruiting |
NCT03846310 -
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
|
Phase 1 |